Denali Therapeutics Inc to Highlight ALS and FTD Development Programs Transcript
Hello, and welcome to the Denali Therapeutics webinar highlighting our therapeutic programs addressing amyotrophic lateral sclerosis or ALS and frontotemporal dementia or FTD.
I am Laura Hansen, Vice President of Investor Relations, and I'd like to thank you for joining us today.
Please note that the press release we issued earlier today and the slide deck for this webinar are available in the investors section of our website, denalitherapeutics.com.
Before we get started, I'd like to note that the presentations given today and the responses to questions will contain forward-looking statements regarding Denali's future plans, business strategy, product candidates, planned preclinical studies and clinical trials, among other things. Such statements are subject to numerous important risks, uncertainties and assumptions. Should any of these risks or uncertainties materialize or should our assumptions prove to be incorrect, our actual results could differ materially from those forward-looking statements. These risks, uncertainties
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |